AIDS-Related Non-Hodgkin's Lymphoma Baseline Lymphoma Disease Activity and Assessment (LAA) Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma NCT00310128 Source Form: NCI FormBuilder:



  1. 8/26/12 8/26/12 -
  2. 2/3/15 2/3/15 - Martin Dugas
  3. 4/13/21 4/13/21 - Dr. rer. medic Philipp Neuhaus
  4. 9/20/21 9/20/21 -
Uploaded on

September 20, 2021


To request one please log in.


Creative Commons BY-NC 3.0 Legacy

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Baseline Lymphoma Disease Activity and Assessment

No Instruction available.

  1. StudyEvent: Baseline Lymphoma Disease Activity and Assessment (LAA)
    1. No Instruction available.
Lymphoma disease activity
Modified Ann Arbor Stage
Recurring, drenching night sweats during the previous month
Unexplained, persistent fever >38 degrees C (or >100 degrees F) in the previous month
Unexplained weight loss above 10% of body weight in the previous 6 months
Hematopoietic Diagnosis
If diffuse large B-cell lymphoma, specify morphologic type
If Burkitt lymphoma/leukemia, specify morphologic type
Method of Evaluation
Is the participant >60 years of age
Does the participant have Stage III or IV disease
Is the serum LDH elevated
Is the ECOG Performance Status 2, 3, or 4
Does the participant have two or more extranodal disease sites
IPI Risk Category

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial